Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of SHR2285 in Healthy Subjects
NCT04472819Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of shr2285 in thrombosis (6 arms), sponsored by Hengrui. Primary endpoints: Number of subjects with adverse events and severity of adverse events, Maximum observed serum concentration for Food Effect and 3 more. Started Aug 2020; status: completed.
02
Drugs
shr2285
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04472819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04472819.